Technology, infrastructure and capital are converging to accelerate the commercialization of space-based R&D, underscored by ...

CD22 is a B cell-restricted antigen expressed on many B-cell malignancies and autoreactive B cells, making it a clinically relevant target alternative to CD19. Umoja Biopharma has developed UB-VV400, ...

The U.S. FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) met to review data from the SYD-101-001 study ...

Bambusa granted underwriters in its IPO a 30-day option to purchase up to an additional 1.6 million shares at the offering ...

Biopharma financings across all categories totaled $29.96 billion in the third quarter (Q3) of 2026, down 14% from $34.8 ...

Japanese researchers have developed a high speed microscopy technique that captures images so quickly it is possible to ...

Driving impressive growth for Eli Lilly and Co., nine-month sales of diabetes and obesity assets Mounjaro and Zepbound (both tirzepatide) are up by 89% and 56%, respectively, over last year, bringing ...

Scientists from the University of Texas MD Anderson Cancer Center recently reported preclinical comparative evaluation of the ...

Bayer AG has won Chinese approval for Sunharbo (asundexian) to prevent recurrent stroke after a noncardioembolic ischemic ...

Stimcardio Medical Inc. raised $30 million in an oversubscribed series A financing round for Rhyvive, its wrist-worn neuromodulation device. The technology is designed to reduce the risk of arrhythmia ...

Nonviral gene delivery is expanding beyond traditional approaches, with researchers exploring modified DNA, transposons, circular RNA and polymer-based nanoparticles to achieve durable expression, ...

Financing, IPOs and M&As are three of the biggest drivers of momentum in the med-tech market, and right now the IPO window is ...